Overview

St. John's Wort Vs. Placebo in Obsessive-Compulsive Disorder.

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the effectiveness of St. John's Wort as compared to placebo (an inactive substance) in the treatment of outpatients with obsessive compulsive disorder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Criteria
Inclusion criteria

- Female patients: at least 2 years post-menopausal, surgically sterile, or practicing a
medically acceptable method of contraception.

- Meets DSM-IV criteria for obsessive compulsive disorder

Exclusion criteria

- Primary diagnosis of major depression, dysthymia, panic disorder, social phobia,
schizophrenia, schizo-affective disorder, bipolar disorder, or PTSD

- Substance abuse or dependence in the past 6 months

- Vascular dementia or primary degenerative dementia of the Alzheimer's type

- Treatment with MAOIs, TCAs, SSRIs, venlafaxine, nefazodone, remeron, citalopram, or
bupropion within 14 days of first visit.

- Fluoxetine within 5 weeks of first visit.

- Failure to respond to at least two adequate antidepressant trials for obsessive
compulsive disorder

- Investigational drugs within 30 days of baseline

- Known allergy or hypersensitivity to St. John's Wort

- Currently in behavior therapy for obsessive compulsive disorder

ALL INQUIRIES WILL UNDERGO A PHONE SCREENING TO DETERMINE WHETHER THEY MEET ELIGIBLITY
REQUIREMENTS.